aid: onkure-therapeutics
name: OnKure Therapeutics
description: 'OnKure Therapeutics (Nasdaq: OKUR) is a publicly traded, clinical-stage biopharmaceutical
  company headquartered in Boulder, Colorado, developing precision medicines for people with cancer. The
  company designs mutant-selective small-molecule inhibitors against oncogenic drivers in the PI3K pathway;
  its lead program OKI-219 is a selective PI3K-alpha H1047R inhibitor in clinical development, with additional
  discovery programs targeting further PI3K-alpha mutations. OnKure became publicly listed through its
  2024 combination with Reneo Pharmaceuticals. It is a therapeutics developer rather than a software vendor:
  it operates a corporate and investor relations web presence and publishes no developer program, public
  API, SDK, or machine-readable API contract.'
url: https://raw.githubusercontent.com/api-evangelist/onkure-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment pass completed; no API surface published
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Precision Medicine
- Clinical Trials
- Life Sciences
- Drug Discovery
- Publicly Traded
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/onkure-therapeutics-domain-security.yml
- type: Website
  url: https://onkuretherapeutics.com/
- type: About
  url: https://onkuretherapeutics.com/about/company/
- type: Support
  url: https://onkuretherapeutics.com/contact/
- type: TermsOfService
  url: https://onkuretherapeutics.com/terms-of-use/
- type: PrivacyPolicy
  url: https://onkuretherapeutics.com/privacy-policy/
- type: InvestorRelations
  url: https://investors.onkuretherapeutics.com/
- type: News
  url: https://investors.onkuretherapeutics.com/news-events/news-releases
- type: LinkedIn
  url: https://www.linkedin.com/company/onkure-tx/
- type: Twitter
  url: https://twitter.com/OnKureTx
- type: WellKnown-Probe
  url: well-known/onkure-therapeutics-well-known.yml
image: https://onkuretherapeutics.com/wp-content/uploads/logo-onkure-color-min.png
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: 'OnKure is a clinical-stage biopharmaceutical company whose product is a drug candidate (OKI-219),
    not software: its onkuretherapeutics.com site is a WordPress marketing presence with only About/Pipeline/Careers/Contact
    sections, the sole machine-readable surface is the default WordPress /wp-json/ CMS endpoint exposing
    Yoast, Wordfence and Redirection plugin routes rather than any OnKure API, and api/developer/docs/graphql/mcp
    subdomains do not resolve in DNS.'
  evidence:
  - url: https://onkuretherapeutics.com/openapi.json
    status: 404
  - url: https://onkuretherapeutics.com/.well-known/agent-card.json
    status: 404
  - url: https://onkuretherapeutics.com/llms.txt
    status: 404
  - url: https://api.onkuretherapeutics.com/openapi.json
    status: 0
  - url: https://onkuretherapeutics.com/wp-json/
    status: 200
  checked: '2026-08-26'